Mark A. Frye

The paper identifies novel CNV loci and dose-dependent gene effects across six psychiatric disorders using genome-wide analysis.

The paper identifies shared and divergent genetic mechanisms across psychiatric disorders using gene-set burden analysis of copy number variants.

The paper develops pathway-specific polygenic scores to predict lithium treatment response in bipolar disorder and finds associations with specific biological pathways.

The paper identifies FNDC4 as a gene associated with alcohol use disorder through GWAS and shows its role in regulating neurogenesis via alternative splicing and CRISPR/Cas9 experiments.

This study integrates genotype, epigenome, and phenotype data to show immune cells contribute to bipolar disorder pathogenesis, heterogeneity, and therapy through epigenomic and genetic mechanisms.

The paper examines the association between insomnia genetic liability and substance use disorders in bipolar disorder patients using polygenic risk scores and electronic health records.

The paper uses targeted metabolomics to analyze changes in acylcarnitines, amines, and lipids in response to citalopram/escitalopram treatment in MDD patients, identifying metabolic correlates of treatment response.

This study identifies metabolomic clusters associated with depressive symptom change and treatment response to CBT in MDD patients.

This study conducts a trans-ancestral GWAS of alcohol dependence, identifying genetic variants and correlations with psychiatric disorders.

The paper shows that polygenic scores for depression traits predict lithium response in bipolar disorder patients, with lower genetic load linked to better treatment outcomes.

This study evaluates polygenic risk scores for MDD and neuroticism as predictors of antidepressant response across three cohorts, finding no significant prediction but consistent directional effects.

This paper conducts a GWAS on suicide attempt across psychiatric disorders, identifying genetic loci and showing polygenic risk for major depression predicts suicide attempt in multiple disorders.

This study finds that a higher genetic risk for schizophrenia is linked to poorer lithium response in bipolar disorder patients, suggesting potential for personalized treatment strategies.